Published Date: 30/04/2013
Category: Therapies & Markets
GBI Research, the leading business intelligence provider, has released its latest research “ADHD Therapeutics Market to 2018 - New Diagnostic Parameters for Adult ADHD Offer Hope for Higher Rates of Treatment”. The report provides insights into the up-and-coming trends of the ADHD market in seven major markets: the US, the top five European countries (France, Germany, Italy, Spain and the UK) and Japan. The report includes market forecasts to 2019, detailed pipeline analysis, in-depth profiling of major products and details of recent industry deals. The report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GBI Research’s team of industry experts.The ADHD therapeutics market is expected to show strong growth in Spain and Japan, with Compound Annual Growth Rates (CAGRs) of 8% and 15% respectively. However, the total revenues of these markets are still expected to be much lower than the largest market, the US, which is expected to reach $6,260m by 2018. This is due to the much higher diagnosis rates for both adults and children with ADHD in the US.
Shire, New River Co, Targacept, AstraZeneca